RVMD Stock Overview
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Revolution Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.87 |
| 52 Week High | US$62.40 |
| 52 Week Low | US$29.55 |
| Beta | 1.37 |
| 1 Month Change | -13.41% |
| 3 Month Change | -25.50% |
| 1 Year Change | 9.06% |
| 3 Year Change | 28.60% |
| 5 Year Change | 38.99% |
| Change since IPO | 13.74% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Revolution Medicines, Inc. (NASDAQ:RVMD) By 49%?
Feb 03
Revolution Medicines: Risky Buy On Recent Share Price Dip
Dec 04Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)
Sep 28This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate
Jun 15Revolution Medicines: On Hold Pending A Lower Entry Point
Jun 04Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Shareholder Returns
| RVMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.7% | -3.1% | -0.9% |
| 1Y | 9.1% | -8.7% | 8.4% |
Return vs Industry: RVMD exceeded the US Biotechs industry which returned -8.7% over the past year.
Return vs Market: RVMD matched the US Market which returned 8.4% over the past year.
Price Volatility
| RVMD volatility | |
|---|---|
| RVMD Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RVMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RVMD's weekly volatility (6%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 534 | Mark Goldsmith | www.revmed.com |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C).
Revolution Medicines, Inc. Fundamentals Summary
| RVMD fundamental statistics | |
|---|---|
| Market cap | US$6.43b |
| Earnings (TTM) | -US$600.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.2x
P/E RatioIs RVMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$592.23m |
| Gross Profit | -US$592.22m |
| Other Expenses | US$7.87m |
| Earnings | -US$600.09m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RVMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 23:36 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revolution Medicines, Inc. is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Alec Stranahan | BofA Global Research |
| Chris Shibutani | Goldman Sachs |